Update on Obesity in Psoriasis Patients.
Dan VataBogdan Marian TarcauIoana Adriana PopescuIoana Alina HalipAdriana Ionela PatrascuDragos-Florin Gheuca SolovastruMadalina MocanuPetronela Cristina ChiriacLaura Gheuca SolovastruPublished in: Life (Basel, Switzerland) (2023)
Psoriasis is a chronic inflammatory skin condition, with genetic, epigenetic, environmental, and lifestyle factors contributing to its onset and recurrence. Severe psoriasis has a great impact on quality of life, which is similar to that of insulin-dependent diabetes, depression, and ischemic heart disease, but with a lower mortality. There is an overlap between the rising incidences of autoimmune diseases and obesity. In recent years, research has shown that there is an association between psoriasis and obesity. Psoriasis is linked to obesity in a two-way manner, as each can precipitate the development of the other. Several adipose tissue-secreted adipokines were shown to be elevated in obese psoriasis patients, exhibiting similar mechanisms of action to those underlying the pathogenesis of psoriasis. Excess body weight can influence not only the treatment response in psoriasis, but also the adverse events, leading to decreased patient compliance. Specific human microbiome patterns have been identified for obesity and psoriasis and could represent a future therapeutic target in selected individuals.
Keyphrases
- metabolic syndrome
- type diabetes
- weight loss
- insulin resistance
- adipose tissue
- end stage renal disease
- high fat diet induced
- atopic dermatitis
- body weight
- newly diagnosed
- chronic kidney disease
- cardiovascular disease
- ejection fraction
- gene expression
- bariatric surgery
- depressive symptoms
- prognostic factors
- patient reported outcomes
- skeletal muscle
- genome wide
- risk factors
- early onset
- coronary artery disease
- risk assessment